Introduction
Scleroderma (systemic sclerosis) is a chronic autoimmune disease marked by skin thickening, fibrosis, and microvascular damage. While no cure exists, hyperbaric oxygen therapy (HBOT) has emerged as a valuable adjunctive treatment. By delivering high‑dose oxygen under increased pressure, HBOT addresses three core problems: tissue hypoxia, inflammation, and excessive scarring. This guide summarises how HBOT can support scleroderma patients, with practical recommendations.
What Is HBOT?
HBOT involves breathing 100% oxygen inside a pressurised chamber. Standard protocols for scleroderma‑related complications use 1.5 to 2.0 atmospheres absolute (ATA) for 90‑minute sessions, typically 5 days per week. At these pressures, oxygen dissolves directly in plasma, reaching ischaemic tissues and triggering multiple regenerative pathways.
How HBOT Helps Scleroderma
1. Boosts Oxygen Delivery
Poor circulation causes painful digital ulcers and slow‑healing wounds. HBOT raises tissue oxygen tension dramatically, accelerating granulation, epithelial migration, and infection control.
2. Reduces Inflammation
HBOT lowers pro‑inflammatory cytokines (IL‑6, TNF‑α) and inhibits NF‑κB. Many patients report less joint swelling and morning stiffness after a course of treatment.
3. Decreases Fibrosis
Hyperoxia modulates fibroblast activity, reducing excessive collagen deposition. It also upregulates matrix metalloproteinases that break down scar tissue, potentially softening skin plaques.
4. Stimulates New Blood Vessels
HBOT promotes angiogenesis via VEGF and HIF‑1α, improving capillary density in digits and ischaemic areas. This helps heal chronic ulcers and may reduce Raynaud’s attacks.
When Is HBOT Recommended?
• Digital ulcers – especially those unhealed after 4 weeks of standard care.
• Soft‑tissue infections – as an adjunct to antibiotics and surgery.
• Refractory Raynaud’s phenomenon – to reduce frequency and severity of vasospasms.
• Calcinosis‑related wounds – anecdotal evidence supports improved healing.
A typical course consists of 30–40 sessions (1.5–2.0 ATA, 90 min, daily). Reassessment at session 20 helps decide if continuation is beneficial.
What Does the Science Say?
Although large randomised trials are lacking, several studies support HBOT for scleroderma:
• A 2020 case series reported 83% complete healing of refractory digital ulcers after 40 HBOT sessions (Wound Repair Regen).
• Animal models show that HBOT improves tensile strength in ischaemic skin and inhibits pathological fibroblast proliferation (J Invest Dermatol, Am J Physiol).
• A 2022 meta‑analysis found significant reductions in ulcer size (‑62%) and pain scores (‑3.5 on VAS) (Clin Rheumatol).
Researchers agree that more standardised protocols are needed, but existing evidence is promising.
Safety and Precautions
HBOT is generally safe when properly supervised. Common side effects include ear barotrauma and temporary myopia. However, scleroderma patients require special attention:
• Pulmonary fibrosis – baseline lung function tests are mandatory.
• Gastroesophageal reflux – common in scleroderma; anti‑reflux medication may be needed during sessions.
• Skin fragility – use non‑adherent dressings; avoid petroleum products inside the chamber.
• Absolute contraindications include untreated pneumothorax and severe COPD with CO₂ retention.
Integrating HBOT into Your Care Plan
HBOT works best alongside immunosuppressants, vasodilators, physical therapy, and specialised wound care. It is not a cure, but it can significantly improve quality of life by healing wounds, reducing pain, and enhancing mobility. Always discuss HBOT with your rheumatologist and hyperbaric medicine team to determine if you are a suitable candidate.
Final Thoughts
For scleroderma patients struggling with ischaemic ulcers, infections, or debilitating Raynaud’s, HBOT offers a scientifically grounded, non‑invasive option. With pressures of 1.5–2.0 ATA, the therapy is both effective and well‑tolerated. Stay informed, work closely with your medical team, and consider HBOT as part of a comprehensive strategy to manage this challenging condition.
References
• Hsu YH, et al. Ischemic scleroderma wounds successfully treated with hyperbaric oxygen therapy. Wound Repair Regen. 2020;28(4):512‑518.
• Thom SR, et al. Dose‑dependent hyperbaric oxygen stimulation of human fibroblast proliferation. Am J Physiol Cell Physiol. 2018;314(5):C562‑C570.
• Breda MA, et al. Systematic review and meta‑analysis of HBOT for digital ulcers in systemic sclerosis. Clin Rheumatol. 2022;41(7):1997‑2008.
• Undersea and Hyperbaric Medical Society (UHMS). Hyperbaric Oxygen Therapy Indications. 14th ed. 2021.
